Exo Simplifies Medical Imaging with New M&A

Exo said it was acquiring Medo to make ultrasound imaging as easy as snapping a smartphone photo.

MDDI Staff

July 27, 2022

1 Min Read
Image courtesy of Cagkan Sayin / Alamy Stock Photo

Exo said it is acquiring Medo, a Canadian developer of artificial intelligence (AI) technology, to make ultrasound imaging faster and simpler to use. By integrating Medo’s proprietary Sweep AItechnology into its ultrasound platform, Exo said it will make ultrasound imaging more accessible to a wider range of caregivers.

Ultrasound imaging is complex and requires specialized education and training. This limits the number of caregivers who can use point-of-care ultrasound to significantly improve patient care. Medo’s unique ultrasound AI technology radically lowers the expertise required to diagnose common and critical conditions through automated image acquisition and interpretation, allowing non-experts to conduct high-quality exams quickly and accurately.

Medo’s two FDA-cleared AI algorithms, with more in development, combined with access to an extensive library of millions of ultrasound images and longitudinal health data bring a unique opportunity to speed point-of-care ultrasound adoption across the healthcare system — dramatically expanding early disease detection and accelerating the path to treatment. Medo also has strong partnerships with health systems worldwide, including top healthcare institutions in Asia and Canada, enabling global clinical validation and adoption.

“This acquisition is about bringing unprecedented ease of use to ultrasound imaging — allowing caregivers to easily obtain and interpret ultrasound images,” said Sandeep Akkaraju, CEO and Founder of Exo. “Medo has built a robust AI pipeline to go from acquiring medical images to FDA-cleared software. We are excited about joining forces with an innovative team that shares our vision of taking medical imaging everywhere.”

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like